(Q41087896)

26 September 2017

title

Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin (English)

1 reference

26 September 2017

0 references

1 reference

1 reference

1 reference

Mitchell L Shiffman

1

1 reference

26 September 2017

Amy M James

series ordinal

2

1 reference

26 September 2017

April G Long

series ordinal

3

1 reference

26 September 2017

Philip C Alexander

series ordinal

4

1 reference

26 September 2017

language of work or name

English

0 references

publication date

28 July 2015

1 reference

The American Journal of Gastroenterology

26 September 2017

published in

1 reference

26 September 2017

volume

110

1 reference

26 September 2017

issue

8

1 reference

26 September 2017

page(s)

1179-1185

1 reference

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

26 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

The global impact of hepatic fibrosis and end-stage liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

When to consider liver transplant during the management of chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

Outcome of sustained virological responders with histologically advanced chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.218

https://api.fatcat.wiki/v0/release/6wkafpodfrcu3b5hc2dbuk4hzu

21 January 2018

Identifiers

1 reference

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_6wkafpodfrcu3b5hc2dbuk4hzu

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6wkafpodfrcu3b5hc2dbuk4hzu

mapped directly with Wikidata item

30 July 2022

based on heuristic

https://api.fatcat.wiki/v0/release/6wkafpodfrcu3b5hc2dbuk4hzu

1 reference